肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2013年
12期
803-805
,共3页
罗海清%官成浓%陈梓宏%杨东红%余忠华
囉海清%官成濃%陳梓宏%楊東紅%餘忠華
라해청%관성농%진재굉%양동홍%여충화
脂质体%紫杉醇%奈达铂%癌,非小细胞肺%药物疗法,联合
脂質體%紫杉醇%奈達鉑%癌,非小細胞肺%藥物療法,聯閤
지질체%자삼순%내체박%암,비소세포폐%약물요법,연합
Liposome%Paclitaxel%Nedaplatin%Carcinoma,non-small-cell lung%Drug therapy,combination
目的 观察紫杉醇脂质体联合奈达铂一线治疗晚期非小细胞肺癌(NSCLC)的临床效果、生存期和患者不良反应.方法 34例晚期NSCLC患者,静脉注射紫杉醇脂质体150 mg/m2,第1天,奈达铂80 mg/ m2,第1天,21d为1个周期.所有患者接受至少2个周期以上化疗,平均每2个周期评估临床疗效、相关不良反应.结果 34例患者均可评价临床疗效和不良反应,患者共接受174个周期化疗,中位化疗周期为5.3个周期,紫杉醇脂质体联合奈达铂的客观反应率为32.3％,疾病控制率为67.6％,中位总生存期为9.5个月(95％CI6.2 ～ 10.7),1年生存率为40.6％.该方案主要的不良反应是血液学和非血液学毒性,其中Ⅲ～Ⅳ度中性粒细胞减少症发生率为41.7％,Ⅲ～Ⅳ度贫血发生率为17.6％,Ⅲ～Ⅳ度血小板减少症发生率为8.8％,Ⅲ～Ⅳ度呕吐发生率为8.8％,Ⅲ～Ⅳ度腹泻发生率为5.8％.结论 紫杉醇脂质体联合奈达铂方案一线治疗晚期NSCLC的临床疗效好,且不良反应较小,患者耐受性好,可作为晚期NSCLC一线化疗的一种新方案.
目的 觀察紫杉醇脂質體聯閤奈達鉑一線治療晚期非小細胞肺癌(NSCLC)的臨床效果、生存期和患者不良反應.方法 34例晚期NSCLC患者,靜脈註射紫杉醇脂質體150 mg/m2,第1天,奈達鉑80 mg/ m2,第1天,21d為1箇週期.所有患者接受至少2箇週期以上化療,平均每2箇週期評估臨床療效、相關不良反應.結果 34例患者均可評價臨床療效和不良反應,患者共接受174箇週期化療,中位化療週期為5.3箇週期,紫杉醇脂質體聯閤奈達鉑的客觀反應率為32.3％,疾病控製率為67.6％,中位總生存期為9.5箇月(95％CI6.2 ～ 10.7),1年生存率為40.6％.該方案主要的不良反應是血液學和非血液學毒性,其中Ⅲ～Ⅳ度中性粒細胞減少癥髮生率為41.7％,Ⅲ～Ⅳ度貧血髮生率為17.6％,Ⅲ～Ⅳ度血小闆減少癥髮生率為8.8％,Ⅲ～Ⅳ度嘔吐髮生率為8.8％,Ⅲ～Ⅳ度腹瀉髮生率為5.8％.結論 紫杉醇脂質體聯閤奈達鉑方案一線治療晚期NSCLC的臨床療效好,且不良反應較小,患者耐受性好,可作為晚期NSCLC一線化療的一種新方案.
목적 관찰자삼순지질체연합내체박일선치료만기비소세포폐암(NSCLC)적림상효과、생존기화환자불량반응.방법 34례만기NSCLC환자,정맥주사자삼순지질체150 mg/m2,제1천,내체박80 mg/ m2,제1천,21d위1개주기.소유환자접수지소2개주기이상화료,평균매2개주기평고림상료효、상관불량반응.결과 34례환자균가평개림상료효화불량반응,환자공접수174개주기화료,중위화료주기위5.3개주기,자삼순지질체연합내체박적객관반응솔위32.3％,질병공제솔위67.6％,중위총생존기위9.5개월(95％CI6.2 ～ 10.7),1년생존솔위40.6％.해방안주요적불량반응시혈액학화비혈액학독성,기중Ⅲ～Ⅳ도중성립세포감소증발생솔위41.7％,Ⅲ～Ⅳ도빈혈발생솔위17.6％,Ⅲ～Ⅳ도혈소판감소증발생솔위8.8％,Ⅲ～Ⅳ도구토발생솔위8.8％,Ⅲ～Ⅳ도복사발생솔위5.8％.결론 자삼순지질체연합내체박방안일선치료만기NSCLC적림상료효호,차불량반응교소,환자내수성호,가작위만기NSCLC일선화료적일충신방안.
Objective To evaluate the clinical efficacy,overall survival and toxicities in the patients with advanced non-small cell lung cancer treated by liposome paclitaxel combined with nedaplatin as first-line treating.Methods 34 cases with advanced NSCLC were treated with liposome paclitaxel 150 mg/m2 on day 1 and nedaplatin 80 mg/m2 on day 1 by intravenous infusion,with 21 days as one cycle.The patients were treated with chemotherapy more than 2 cycles.Efficacy evaluation and adverse events were evaluated every 2 cycles.Results 34 patients were available for evaluation of efficacy and adverse events.The patients recieved 174 cycles of chemotherapy,and the median was 5.3 cycles.The objective response rate of liposome paclitaxel combined with nedaplatin was 32.3 ％,the disease control rate was 67.6 ％,the median overall survival was 9.5 months (95 ％ CI 6.2-10.7),1 years survival rate was 40.6 ％.The main adverse events were hematological and gastrointestinal toxicities.Frequent grade Ⅲ-Ⅳ toxicities included neutropenia (41.7 ％),anemia (17.6 ％),thrombocytopenia (8.8 ％),nausea and vomiting (8.8 ％),diarrhea (5.8 ％).Conclusions The regimen of liposome paclitaxel combined with nedaplatin is against advanced non-small cell lung cancer with high efficacy and acceptable toxicities,and it may be used as a new choice for treatment of advanced non-small cell lung cancer.
